Chronic obstructive pulmonary disease: The clinical management of an acute exacerbation

Postgraduate Medical Journal

Volumn 80, Issue 947, 2004, Pages 497-505

  Hurst, J R ^a   Wedzicha, J A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMINOPHYLLINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOXAPRAM; IPRATROPIUM BROMIDE; MACROLIDE; METHYLPREDNISOLONE; METHYLXANTHINE DERIVATIVE; PREDNISOLONE; SALBUTAMOL; TETRACYCLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSENSUS; DISEASE EXACERBATION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; REVIEW; TREMOR;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; HUMANS; OXYGEN; PHYSICAL EXAMINATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL; RESPIRATORY SYSTEM AGENTS; XANTHINES;

EID: 4644297383     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.019182     Document Type: Review

References (95)

1. Pauwels R, Anthonisen N, Bailey WC, et al. Global initiative for chronic obstructive lung disease. National Heart, Lung and Blood Institute, National Institutes of Health, 2001.
2. Donaldson GC, Seemungal TAR, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003;22:931-6.
3. 1 as predictors of hospitalization and medication in the following 12 years due to respiratory disease. Eur Respir J 1989;2:710-15.
4. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
5. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(suppl):398S-408S.
6. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23.
7. Greenberg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-73.
8. Donaldson GC, Seemungal T, Jeffries DJ, et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J 1999;13:844-9.
9. Seemungal TAR, Harper-Owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000;16:677-83.
10. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999;13:343-8.
11. Patel IS, Seemungal TAR, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 2002;57:759-64.
12. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-5.
13. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
14. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45.
15. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997;10:1064-71.
16. Lung and Asthma Information Agency. Trends in emergency hospital admissions for lung disease. Fact sheet 2001/4. London: St George's Hospital Medical School.
17. Ashton CM, Ferguson JA, Goldacre MJ. In-patient workload in medical specialities-2. Profiles of individual diagnoses from linked statistics. Q J Med 1995;88:661-72.
18. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996;154:959-67.
19. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-64.
20. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
21. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117(suppl):5S-9S.
22. American Thoracic Society. Standards for the diagnosis of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
23. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003. Can Respir J 2003;10(suppl A):11A-65A.
24. European Respiratory Society Task Force. Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J 1995;8:1398-420.
25. COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(suppl 5):S1-S28.
26. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease (COPD): management of chronic obstructive pulmonary disease in primary and secondary care. Thorax 2004;59(suppl):i1-i232.
27. Warren PM, Flenley DC, Millar JS, et al. Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76. Lancet 1980;i:467-70.
28. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967-75.
29. Braun SR, McKenzie WN, Copeland C, et al. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med 1989;149:544-7.
30. McCrory DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease (Cochrane methodology review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
31. Turner MO, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997;157:1736-44.
32. Turner MO, Gafni A, Swan D, et al. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med 1996;156:2113-18.
33. Levitt MA, Gambrioli EF, Fink JB. Comparative trial of continuous nebulization versus metered-dase inhaler in the treatment of acute branchospasm. Ann Emerg Med 1995;26:273-7.
34. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52.
35. Bhowmik A, Seemungal TAR, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
36. Singh JM, Palda VA, Stanbrook MB, et al. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease. A systematic review. Arch Intern Med 2002;162:2527-36.
37. Wood-Baker R, Walters EH, Gibson P. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (Cochrane methodology review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
38. Murata GH, Gorby MS, Chick TW, et al. Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD. Effect on patients with a history of multiple relapses. Chest 1990;98:845-9.
39. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
40. O'Driscoll BR, Kalra S, Wilson M, et al. Double-blind trial of steroid tapering in acute asthma. Lancet 1993;341:324-7.
41. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
42. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980;92:753-8.
43. Maltois F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med 2002;165:698-703.
44. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
45. Sachs APE, Koeter GH, Groenier KH, et al. Changes in symptoms peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995;50:758-63.
46. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
47. Adam S, Melo J, Anuzueto A. Effects of antibiotics on the recurrence rates of chronic obstructive pulmonary disease exacerbations. Chest 1997;112(suppl):22S.
48. Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;43(suppl A):107-13.
49. Powell M, McVey D, Kassim MH, et al. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamellea) catarrhalis isolated in the UK from sputa. J Antimicrob Chemother 1991;28:249-59.
50. Sin DD, Tu JV. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Can Respir J 2000;7:466-71.
51. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003;327:643-6.
52. Angus RM, Ahmed AA, Fenwick U, et al. Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease. Thorax 1996;51:1048-50.
53. Greenstone M, Lasserson TJ. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease [Cochrane methodology review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
54. Barbera JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997;10:1285-91.
55. Plant PK, Owen J, Elliot MW. One year period prevalence study of respiratory acidosis in acute exacerbation of COPD: implications for the provision of non-invasive ventilation and oxygen administration. Thorax 2000;55:550-4.
56. Robinson TD, Freiberg DB, Regnis JA, et al. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1524-9.
57. Moloney ED, Kiely JL, McNicholas WT. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease. Lancet 2001;357:526-8.
58. Costello RW, Liston R, McNicholas WT. Compliance at night with low flow oxygen therapy: a comparison of nasal cannulae and Venturi face masks. Thorax 1995;50:405-6.
59. Agusti AGN, Carrera M, Barbe F, et al. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999;14:934-9.
60. Fajac I, Texereau J, Rivoal V, et al. Blood gas measurement during exercise: a comparative study between arterialized earlobe sampling and direct arterial puncture in adults. Eur Respir J 1998;11:712-5.
61. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993;341:1555-7.
62. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.
63. Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995;151:1799-806.
64. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000;355:1931-5.
65. Lightowler JV, Wedzicha JA, Elliott MW, et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbation chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003;326:185-7.
66. Keenan SP, Gregor J, Sibbald WJ, et al. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med 2000;28:2094-102.
67. Plant PK, Owen JL, Parrott S, et al. Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. BMJ 2003;326:956-9.
68. Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation. A 28-day international study. JAMA 2002;287:345-55.
69. Purro A, Appendini L, De Gaetano A, et al. Physiologic determinants of ventilator dependence in long-term mechanically ventilated patients. Am J Respir Crit Care Med 2000;161:1115-23.
70. Nave S, Ambrosino N, Clini E, et al. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. Ann Intern Med 1998;128:721-8.
71. Rodrigo G, Pollack C, Rodrigo C, et al. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease (Cochrane review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
72. Garcia-Aymerich J, Monso E, Marrades RM, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM Study. Am J Respir Crit Care Med 2001;164:1002-7.
73. Ram FSF, Wedzicha JA, Wright J, et al. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease (Cochrane review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
74. Shepperd S, Harwood D, Jenkinson C, et al. Randomised controlled trial comparing hospital at home care with inpatient hospital care. I: three month follow up of health outcomes. BMJ 1998;316:1786-91.
75. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80.
76. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
77. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
78. Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-6.
79. Alsaeedi A, Sin DS, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
80. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 1999;159:941-55.
81. Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD. A randomized trial. Am J Respir Crit Care Med 2000;162:174-8.
82. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
83. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 years treatment with tiotropium. Eur Respir J 2002;19:209-16.
84. Poole PJ, Chacko E, Wood-Baker RWB, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease (Cochrane review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
85. Williams JH Jr, Moser KM. Pneumococcal vaccine and patients with chronic lung disease. Ann Intern Med 1986;104:106-9.
86. Davis AL, Aranda CP, Schiffman G, et al. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 1987;92:204-12.
87. Stoykova T, Black P, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis (Cochrane review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
88. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease (Cochrane review). The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons.
89. Collet JP, Shapiro S, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:1719-24.
90. Foglio K, Bianchi L, Bruletti G, et al. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J 1999;13:125-32.
91. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD. A randomised trial. Chest 2000;117:976-83.
92. Leger P, Bedicam JM, Cornette A, et al. Nasal intermittent positive pressure ventilation. long-term follow-up in patients with severe chronic respiratory insufficiency. Chest 1994;105:100-5.
93. Jones SE, Packham S, Hebden M, et al. Domiciliary nocturnal intermittent positive pressure ventilation in patients with respiratory failure due to severe COPD: long term follow up and effect on survival. Thorax 1998;53:495-8.
94. Perrin C, El Far Y, Vandenbos F, et al. Domiciliary nasal intermittent positive pressure ventilation in severe COPD: effects on lung function and quality of life. Eur Respir J 1997;10:2835-9.
95. Tuggey JM, Plant PK, Elliott MW. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis. Thorax 2003;58:867-71.